IL20 and breast cancer: The therapeutic effects of anti-IL-20 monoclonal antibody (7E) were evaluated in oral cancer and BC in vivo models, in which 7E alleviated key malignant phenotypic characteristics by inhibiting tumor growth and tumor size [80].